Defence Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DTCFF research report →
Price Chart
About the company
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; the anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; the ARM-X vaccine program, a mesenchymal stem cell-based vaccine targeting cancer; and mRNA vaccination program.
- CEO
- Amie Phinney
- IPO
- 2021
- Employees
- 1,300
- HQ
- Vancouver, BC, CA
Get TickerSpark's AI analysis on DTCFF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $26.10M
- P/E
- -4.43
- PEG
- 0.11
- P/S
- 0.00
- P/B
- 5.40
- EV/EBITDA
- -6.02
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -1661.38%
- ROIC
- -53.54%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-3,000,000
- Net Income
- $-4,000,000+69.7%
- EPS
- $-0.05+82.7%
- OCF Growth
- +30.0%
- FCF Growth
- +33.2%
- 52W High
- $0.78
- 52W Low
- $0.25
- 50D MA
- $0.32
- 200D MA
- $0.43
- Beta
- 1.35
- RSI (14)
- 58
- Avg Volume
- 7.85K
No earnings-call transcripts are available for DTCFF yet.
- Free Float
- 89.5%
- Shares Outstanding
- 75.79M
- Float Shares
- 67.83M
Our DTCFF coverage
Recent articles, reports, and earnings notes.
No research on DTCFF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DTCFF report →Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs
newsfilecorp.com · Aug 17
Defence Therapeutics Appoints Dr. Amie Phinney as President and Chief Executive Officer
newsfilecorp.com · Aug 4
Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform
newsfilecorp.com · Jul 8
Defence Therapeutics to Participate in Bio International Convention 2026 Next Week for Strategic Partnership Discussions
newsfilecorp.com · Jun 17
Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors
newsfilecorp.com · Jun 3
Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of Directors
newsfilecorp.com · Jun 1
Defence Therapeutics Strengthens Its Scientific Advisory Board with the Appointment of Dr. Sarkis Meterissian
newsfilecorp.com · May 29
Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities
newsfilecorp.com · May 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.